OTC Switch Pathway Abroad Looks Smoother, But Payoffs Are Lower
This article was originally published in The Tan Sheet
Executive Summary
Switching new Rx drug categories to OTC abroad may appeal to firms put off by the trickle of switches in the U.S., but the payoff abroad is smaller and there is no guarantee FDA will follow another government's decision, experts say